Referanslar: 1) Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062.
2) Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumoniaJ Thromb Haemost. 2020 Apr;18(4):844-847.
3) Wang T, Chen R, Liu C, Liang W, Guan W, Tang R, Tang C, Zhang N, Zhong N, Li S. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020 May;7(5):e362-e363.
4) Hayıroğlu Mİ, Çınar T, Tekkeşin Aİ. Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature reviewRev Assoc Med Bras (1992). 2020 Jun;66(6):842-848.
5) Buijsers B, Yanginlar C, Maciej-Hulme ML, de Mast Q, van der Vlag J.
Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patientsEBioMedicine. 2020 Aug 24;59:102969.
6) https://covid19.saglik.gov.tr/TR-66341/antisitokin-antiinflamatuar-tedaviler-koagulopati-yonetimi.html#
7) Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, Yaffe MB, Moore HB, Barrett CD. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series J Thromb Haemost. 2020 Jul;18(7):1752-1755.
8) Barrett CD, Moore HB, Moore EE et al (2020) Fibrinolytic therapy for refractory COVID-19 acute respiratory distress syndrome: scientific rationale and review. Res Pract Thromb Haemost 4:524–531